A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.

NCT04335006 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

80

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor R \& D Strategy Adjustment

Conditions

Breast Cancer
Triple Negative Breast Cancer

Interventions

DRUG: Carelizumab
DRUG: Nab-paclitaxel
DRUG: Apatinib

Sponsor

Jiangsu HengRui Medicine Co., Ltd.